Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction

N

Naval Hospital, Athens

Status

Unknown

Conditions

Dry Eye
Meibomian Gland Dysfunction
Dry Eye Syndromes

Treatments

Procedure: laser light

Study type

Interventional

Funder types

Other

Identifiers

NCT04425551
6/19

Details and patient eligibility

About

The modern treatment of meibomian gland dysfunction(MGD) is based on anti-inflammatory drops or oral antibiotics for decreasing dry eye disease (DED) associated inflammation, warm compresses for liquefying the thicker meibum, and lid hygiene for reducing the bacterial overload. But, such treatments have shown limited effectiveness to a large proportion of patients with MGD, due to the multifactorial background of the disease. Thus, alternative approaches aiming at different aspects of the DED pathophysiology are needed. Elimination of posterior lid-margin hyperemia with telangiectasia could be a treatment target for reducing the secretion of inflammatory mediators in the course of MGD. Using the mechanism of photocoagulation via selective thermolysis, laser light could contribute to the destruction of abnormal vessels at the posterior lid-margin and thus, the reduction of inflammation. Recently, sub-threshold (micropulse) laser photocoagulation was introduced in ophthalmology and offers significant clinical advantages compared to conventional continuous wave (CW) approach, preventing laser induced thermal damage and related treatment side effects. This study investigates the effect of sub-threshold (micropulse) laser treatment for dry eye disease due to meibomian gland dysfunction combined with increased eyelid margin vascularity.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 18-80 years
  • chief complaint of more than one of dryness, foreign-body sensation, burning, and tearing for 3 months
  • diagnosis of MGD with palpebral telangiectasia in both eyes

Exclusion criteria

  • ocular structural abnormalities
  • history of ocular trauma or surgery
  • use of any treatment for DE or MGD, other than artificial tears, within the past month
  • active allergy, infection, or inflammatory disease at the ocular surface unrelated to DE or MGD
  • lacrimal drainage-system anomalies
  • contact-lens wear
  • use of any systemic anti-inflammatory medicine

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

15 participants in 2 patient groups

Treated
Active Comparator group
Description:
The lower eyelid margin of the clinically worse eye was selected for treatment. A slit lamp based 532 nm optically pumped dual diode solid state SP-Mode (subthreshold) laser system was used. After cleaning eyelids with a cosmetic face wash, a drop of proparacaine hydrochloride 0.5% was then administered onto the conjunctival sac. No eye or cornea shield was used, since laser light was directly aimed at telangiectasias. The treatment parameters were set with 50 μm spot size and 200 ms duration with 30% duty cycle. The power ranged from 1500 to 1700 mW with monospot micropulse model and a just visible destruction of the telangiectatic vessels served as the threshold burn. After the procedure, the patient received corticosteroid ointment for 5 days on both eyes and was advised to continue applying her pre-treatment medication on both eyes.
Treatment:
Procedure: laser light
Untreated
No Intervention group
Description:
The lateral eye was observed as control.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems